Understand the source comparison
Best Peptides for MCAS / CIRS Researchers: Evidence-Based Comparison
BPC-157 Mast cell membrane stabilisation, nitric oxide modulation Vascular permeability, histamine-induced leakage 500–2000 mcg daily Rodent models show 60% reduction in vascular leakage (Biomedicine & Pharmacotherapy, 2019) Strongest mechanistic fit for MCAS.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Mast cell membrane stabilisation, nitric oxide modulation
- Vascular permeability, histamine-induced leakage
- 500–2000 mcg daily
- Rodent models show 60% reduction in vascular leakage (Biomedicine & Pharmacotherapy, 2019)
- Strongest mechanistic fit for MCAS. Addresses degranulation and downstream vascular effects
- Thymosin Beta-4
- Cytokine downregulation (IL-6, TNF-alpha), epithelial repair
- Inflammatory cytokine storm, mucosal barrier integrity
- 2–10 mg twice weekly
- 45% reduction in mast cell degranulation in ovalbumin model (Frontiers in Immunology, 2017)
- Best option for multi-system repair. Tissue regeneration plus immune modulation
- LL-37
- Antimicrobial peptide, biotoxin neutralisation, TLR4 modulation
- Biotoxin clearance (mycotoxins, LPS), innate immune dysregulation
- 200–500 mcg daily
- 70% reduction in LPS-induced TNF-alpha (Karolinska Institute, in vitro)
- Only peptide with direct antimicrobial activity against CIRS biotoxins
- Epithalon
- Telomerase activation, circadian melatonin regulation
- HPA axis dysfunction, circadian disruption
- 5–10 mg per 10-day cycle
- Normalises melatonin in pinealectomised rats (Neuroendocrinology Letters, 2016)
- Addresses sleep and HPA dysregulation. Secondary but critical pathway
- Selank
- BDNF modulation, IL-6 reduction, anxiolytic without sedation
- Neuroinflammation, cognitive dysfunction ('brain fog')
- 300–600 mcg daily
- 40% IL-6 reduction in stressed rats (Neuropeptides, 2015)
- Targets neuroinflammatory symptoms. Useful adjunct, not primary intervention
- KPV
- NF-kappaB inhibition, alpha-MSH mimetic
- MSH suppression (CIRS hallmark), downstream cytokine production
- 500–1000 mcg subcutaneous
- 80% reduction in TNF-alpha and IL-8 in LPS-stimulated cells (in vitro)
- Mechanistic fit for CIRS. Mimics MSH activity that biotoxins suppress